Markus Jensen

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans et al. · Journal of Clinical Oncology · 2014 · 577 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

Marc Beyer, Matthias Kochanek, Kamruz Darabi et al. · Blood · 2005 · 488 citations

Life Sciences, Hematology, Immunology +16

Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial

Thomas Elter, Peter Borchmann, H. Schulz et al. · Journal of Clinical Oncology · 2005 · 212 citations

Medicine, Oncology, Pharmacotherapy +17

Breaking of B cell tolerance toward a highly conserved self protein

Iben Dalum, Markus Jensen, Peter Hindersson et al. · The Journal of Immunology · 1996 · 76 citations

Life Sciences, Immunology, Molecular Biology +17

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

Stefan Willmann, Eleonora Marostica, Nelleke Snelder et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 39 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16